Key points are not available for this paper at this time.
In this trial involving patients with ANCA-associated vasculitis, avacopan was noninferior but not superior to prednisone taper with respect to remission at week 26 and was superior to prednisone taper with respect to sustained remission at week 52. All the patients received cyclophosphamide or rituximab. The safety and clinical effects of avacopan beyond 52 weeks were not addressed in the trial. (Funded by ChemoCentryx; ADVOCATE ClinicalTrials.gov number, NCT02994927.).
Building similarity graph...
Analyzing shared references across papers
Loading...
David Jayne
Peter A. Merkel
Thomas J. Schall
New England Journal of Medicine
University of Pennsylvania
Addenbrooke's Hospital
Philadelphia University
Building similarity graph...
Analyzing shared references across papers
Loading...
Jayne et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d73b77aa68b335b4f30940 — DOI: https://doi.org/10.1056/nejmoa2023386